Skip to main content

Research

Our researches Plan:

1- Development, study in depth of pharmaceutical organic chemistry and illustration of its synthetic, mechanistic, and industrial applications.

2- Design and synthesis of different classes of compounds such as: Triazoles, benzimidazoles, piperazinedione and thiadiazine derivatives and others A special focus on xanthine and pyridazinone derivatives

3- Structural elucidation of the target compounds utilizing: IR,1H-NMR, MS in addition to elemental analysis Optical Rotation

4- Biological screening: Antimicrobial: antibacterial, antifungal and antituberculosis in addition to anthlemintic activity. Anti-inflammatory, analgesic, antipyretic activities and ulcerogenicity determination. Cardiotonic and hypotensive activities. Hypoglycemic activity. Anticonvulsant activity.

5- Other titles in consideration: Synthesis of new dendimers of potential biological activity. Applications of photochemical reactions for synthesis of certain organic compounds of potential biological activity. Synthesis of some antineurodegenerative compounds. Synthesis of certain nucleosides of potential biological activity. Synthesis of certain adenine derivatives of possible antiviral activity.

# Title Research Year
21 Design and synthesis of New dihydropyrimidine/sulphonamide hybrids as promising anti-inflammatory agents via dual mPGES-1/5-LOX inhibition 2024
22 Design and synthesis of novel quinoline-ester/-amide derivatives as potent antiproliferative agent targeting EGFR and BRAFV600E kinases 2024
23 Design, synthesis and mechanistic anticancer activity of new acetylated 5-aminosalicylate-thiazolinone hybrid derivatives 2024
24 Design, synthesis, and antiproliferative activity of new 1, 2, 3-triazole/quinazoline-4-one hybrids as dual EGFR/BRAF V600E inhibitors 2024
25 Design, synthesis, and antiproliferative activity of new indole/1,2,4-triazole/chalcone hybrids as EGFR and/or c-MET inhibitors 2024
26 Design, synthesis, and apoptotic antiproliferative action of new 1,2,3-triazole/1,2,4-oxadiazole hybrids as dual EGFR/VEGFR-2 inhibitors 2024
27 Design, synthesis, and biological evaluation of novel quinoline-based EGFR/HER-2 dual-target inhibitors as potential antitumor agents 2024
28 Design, synthesis, biological evaluation and docking study of some new aryl and heteroaryl thiomannosides as FimH antagonists. 2024
29 Discovery of new Schiff bases of the disalicylic acid scaffold as DNA gyrase and Topoisomerase IV inhibitors endowed with antibacterial properties 2024
30 Hybrids of 4-aminosalicylic acid with dual anti-mycobacterial and anti-inflammatory activities: Synthesis, biological evaluation, in silico investigation and structure-activity relationships exploration 2024